GlassScriptPhysician profile
Danielle A Grate
NPI 1356415558
$8,831.89
in general payments reported to CMS, 2019-2025
40 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $24.23 · 2022: $2,135 · 2023: $2,207 · 2024: $2,287 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,672.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $963.42 | 2022-2025 | Minimed 780g, Simplera Sensor, Minimed 770g |
| Lilly USA, LLC | $865.19 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $752.92 | 2022-2025 | Korlym |
| Mannkind Corporation | $561.25 | 2022-2025 | Afrezza |
| Amgen INC. | $537.57 | 2022-2025 | Tepezza, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.93 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $386.21 | 2022-2025 | Sogroya, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $383.62 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $373.00 | 2022-2025 | |
| Dexcom, INC. | $335.24 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $299.89 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $250.27 | 2022-2025 | Strensiq |
| Abbott Laboratories | $247.40 | 2022-2025 | Freestyle Libre 3, Eterna |
| Radius Health, INC. | $242.70 | 2022-2024 | Tymlos |
| Ascendis Pharma Endocrinology INC | $218.21 | 2023-2025 | Yorvipath |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $213.58 | 2023-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $198.21 | 2021-2025 | |
| Horizon Therapeutics Plc | $173.00 | 2022-2023 | Tepezza |
| Antares Pharma, INC. | $164.81 | 2024-2025 | Xyosted |
| Ascensia Diabetes Care US INC. | $146.20 | 2023-2025 | |
| Grt US Holding, INC. | $125.87 | 2022 | |
| Almatica Pharma LLC | $117.05 | 2024-2025 | Teriparatide, Loreev Xr |
| Kyowa Kirin, INC. | $115.43 | 2023-2025 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $95.49 | 2022 | |
| Insulet Corporation | $95.47 | 2022 | |
| Astellas Pharma US INC | $88.25 | 2023-2025 | Veozah |
| Madrigal Pharmaceuticals | $67.79 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $51.79 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Chiesi USA, INC. | $51.54 | 2024 | Mycapssa |
| Neurocrine Biosciences, INC. | $47.75 | 2024-2025 | |
| Ibsa Pharma INC. | $39.89 | 2023 | Tirosint, Licart |
| Halozyme INC | $28.14 | 2023 | |
| Alvogen INC | $26.05 | 2024 | Teriparatide |
| Amryt Pharma Holdings LTD | $24.42 | 2023 | Myalept |
| Beta Bionics, INC. | $23.75 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Pfizer INC. | $22.83 | 2022 | |
| Verity Pharmaceuticals INC. | $22.20 | 2025 | Tlando |
| Rgh Enterprises LLC | $20.89 | 2023 | |
| Zealand Pharma US, INC. | $16.45 | 2022 | |
| Averitas Pharma INC. | $16.22 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$156.24 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Grate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.